Author:
Wang Kai,Song Kai,Ma Zhigang,Yao Yang,Liu Chao,Yang Jing,Xiao Huiting,Zhang Jiashuai,Zhang Yanqiao,Zhao Wenyuan
Abstract
Abstract
Background
Our laboratory previously reported an individual-level prognostic signature for patients with stage II colorectal cancer (CRC). However, this signature was not applicable for RNA-sequencing datasets. In this study, we constructed a robust epithelial-to-mesenchymal transition (EMT)- related gene pair prognostic signature.
Methods
Based on EMT-related genes, metastasis-associated gene pairs were identified between metastatic and non-metastatic samples. Then, we selected prognosis-associated gene pairs, which were significantly correlated with disease-free survival of stage II CRC using multivariate Cox regression model, as the EMT-related prognosis signature.
Results
An EMT-related signature composed of fifty-one gene pairs (51-GPS) for prediction-relapse risk of patients with stage II CRC was developed, whose prognostic efficiency was validated in independent datasets. Moreover, 51-GPS achieved better predictive performance than other reported signatures, including a commercial signature Oncotype Dx colon cancer and an immune-related gene pair signature. Besides, EMT-related functional gene sets achieved high enrichment scores in high-risk samples. Especially, loss-of-function antisense approach showed that DEGs between the predicted two clusters were metastasis-related.
Conclusions
The EMT-related gene pair signature can identify the high relapse-risk patients with stage II CRC, which can facilitate individualised management of patients.
Funder
National Natural Science Foundation of China
Applied Technology Research and Development Plan of Heilongjiang Province
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Can J. Clin. 68, 394–424 (2018).
2. Vicuna, B. & Benson, A. B. Adjuvant therapy for stage II colon cancer: prognostic and predictive markers. J. Natl Compr. Cancer Netw. 5, 927–936 (2007).
3. Hari, D. M., Leung, A. M., Lee, J. H., Sim, M. S., Vuong, B., Chiu, C. G. et al. AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? J. Am. Coll. Surg. 217, 181–190 (2013).
4. Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y.-J., Ciombor, K. K. et al. NCCN guidelines insights: colon cancer, version 2.2018. J. Natl Compr. Cancer Netw. 16, 359–369 (2018).
5. Van Cutsem, E. & Oliveira, J. Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann. Oncol. 20(Suppl 4), iv49–iv50 (2009).
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献